Alector Inc

Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Alector Inc reports robust earnings, advances Alzheimer's therapy development

Alector Inc's Q2 2023 earnings call highlighted strong financial performance, progress in late-stage clinical programs, and a focus on immuno-neurology research.
The company faces challenges in trial management and disease progression variability but benefits from a solid cash position and collaboration revenue.
Opportunities lie in upcoming milestones, conference participation, and the potential of AL002 therapy, positioning Alector for continued growth and innovation.

Alector Inc reports strong Q4 performance and advances in neurodegenerative treatments

Alector Inc's Q4 performance reflects significant achievements in late-stage programs, strong financial standing, and positive patient engagement, underlining progress in neurodegenerative disease treatment.
The company's strengths in immuno-neurology, blood-brain barrier technology, and strategic partnerships position them well for addressing Alzheimer's disease and exploring accelerated approval pathways.
Challenges in trial design, biomarker assessment, and resource allocation require careful navigation, while opportunities in therapeutic delivery enhancement and disease progression slowing offer avenues for growth and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Promotion demonstrates Alector's commitment to building a world-class culture that questions convention, embraces feedback and promotes development for all employees

Alector Announces Promotion of Clare Hunt to Chief People Officer

Initiation of phase 1 study of first clinical drug AL044 targeting MS4A for Alzheimer's Disease has been achieved. AbbVie for now remains committed with Alector in advancing AL002, which targets TREM2 for Alzheimer's Disease, in the ongoing INVOKE-2 phase 2 study.

Alector: Advancement Of Third Alzheimer's Drug Brings About Huge Potential

Apple

Caterpillar

Celsius Holdings

Clearfield

Invesco Treasury Collateral ETF

Chevron

Dow Inc

Enphase Energy

Alphabet

G1 Therapeutics

Intrepid Potash

Johnson & Johnson

JPMorgan Chase & Co

McDonald's

Merck

Microsoft

Direxion Daily Semiconductor Bull 3x Shares

SPDR S&P 500 ETF Trust

TravelCenters of America

Tidewater

Direxion Daily Utilities Bull 3X Shares

Viridian Therapeutics

Wave Life Sciences

Zymeworks Inc

Two new Breakout Stocks for Week 40 with better than 10% short-term upside potential and one Dow 30 pick. Average cumulative returns now up to +105.6% YTD. This week 2 picks beat 10% in less than a week with FUSN +12.2%, LRMR at +12.95% and VYGR +9.2% peak gains continuing in high negative Momentum Gauge warnings.

MDA Breakout Stocks Week 40 - October 2022: Short-Term Picks To Give You An Edge

AL044 is the first clinical-stage drug candidate targeting MS4A, a major genetic risk factor for AD

Alector Initiates Phase 1 Clinical Trial of AL044 for the Treatment of Alzheimer's Disease (AD)

The consensus price target hints at a 58.2% upside potential for Alector (ALEC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Believe Alector (ALEC) Could Rally 58%: Here's is How to Trade

Alector (ALEC) delivered earnings and revenue surprises of 130.77% and 64.05%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Alector (ALEC) Q2 Earnings and Revenues Beat Estimates

Results from the phase 3 INFRONT-3 study using AL001 for the treatment of patients with Frontotemporal dementia are expected in 2023. Alector holds the potential to advance AL001 for both FTD-GRN and FTD-C9orf72 patients, plus several other neurological indications like Alzheimer's Disease and Parkinson's Disease.

Alector: Potential In Neurology And Cancer Treatments

SOUTH SAN FRANCISCO, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on Wednesday, June 15, 2022, at 2:00 p.m. PT.

Alector to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 27, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the compensation committee of Alector's board of directors granted Gary Romano, M.D., Ph.D., the company's newly-hired Chief Medical Officer, an inducement equity grant on May 27, 2022, consisting of inducement stock options to purchase an aggregate of 369,000 shares of the company's common stock and inducement restricted stock units, or RSUs, covering an aggregate of 92,250 shares of the company's common stock. These inducement stock options and inducement RSUs are subject to the terms of Alector's 2022 Inducement Equity Incentive Plan and related forms of agreements and were granted as inducements material to new employees entering into employment with Alector in accordance with Nasdaq Listing Rule 5635(c)(4).

Alector Reports Inducement Grants as permitted by the Nasdaq Listing Rules

Alector (ALEC) delivered earnings and revenue surprises of -245.95% and 73.28%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Alector (ALEC) Reports Q1 Loss, Misses Revenue Estimates

SOUTH SAN FRANCISCO, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will participate in a fireside chat at the BofA Securities 2022 Healthcare Conference on Thursday, May 12, 2022, at 11:20 a.m. PT.

Alector to Participate at the BofA Securities 2022 Healthcare Conference

Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Alector (ALEC) to Report Q1 Results: Wall Street Expects Earnings Growth

Alector has a novel approach to neurodegenerative diseases. Alector thinks that the immune system gone wrong causes those diseases.

Alector: Expect Phase 3 Data Next Year

SOUTH SAN FRANCISCO, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the appointment of Gary Romano, M.D., Ph.D., as Chief Medical Officer. In this role, Dr. Romano will lead the company's global clinical development strategy, including oversight of the clinical development, clinical operations, biometrics and digital science, and medical affairs functions. Dr. Romano will report to Sara Kenkare-Mitra, Ph.D., President and Head of Research and Development of Alector. Dr. Romano's appointment is effective May 23, 2022.

Alector Announces Appointment of Gary Romano, M.D., Ph.D., as Chief Medical Officer

New York, New York--(Newsfile Corp. - March 24, 2022) - Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Alector, Inc. (NASDAQ: ALEC) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.If you own ALEC please contact Justin Kuehn, Esq. by email at jkuehn@moorekuehn.com or telephone at (212) 709-8245. The consultation...

Moore Kuehn, PLLC Encourages Investors of Alector, Inc. to Contact Law Firm

Treatment with AL001 (latozinemab) demonstrated target engagement and resulted in increases in progranulin levels in all patients

Alector Presents AL001 (latozinemab) Data from the FTD-C9orf72 Cohort of the INFRONT-2 Phase 2 Clinical Trial

SOUTH SAN FRANCISCO, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering the discovery and development of immuno-neurology therapeutics, today announced management will participate in a panel discussion at the Cowen Annual Health Care Conference on Tuesday, March 8, 2022, at 2:10 p.m. ET.

Alector to Participate at the Cowen 42nd Annual Health Care Conference

Alector (ALEC) delivered earnings and revenue surprises of -423.08% and 81.43%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Alector (ALEC) Reports Q4 Loss, Lags Revenue Estimates

CTAD and SITC presentations in fourth quarter highlight progress across  immuno-neurology and immuno-oncology portfolio

Alector Reports Fourth Quarter and Full Year 2021 Financial Results

Will Alector (ALEC) Report Negative Q4 Earnings? What You Should Know

SOUTH SAN FRANCISCO, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering the discovery and development of immuno-neurology therapeutics, today announced the appointment of Marc Grasso, M.D., as Chief Financial Officer (CFO). Dr. Grasso brings extensive biotechnology industry leadership experience, including a successful track record in finance, corporate development and strategic leadership. As Alector's CFO, Dr. Grasso will lead all aspects of the company's financial operations and play a critical role in supporting corporate strategy. Dr. Grasso will report to Arnon Rosenthal, Ph.D., Chief Executive Officer of Alector.

Alector Announces Appointment of Marc Grasso, M.D., as Chief Financial Officer

Alector (ALEC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Alector (ALEC) Surges 8%: Is This an Indication of Further Gains?

Biotech companies have seen an economic boom lately thanks to the COVID-19 Pandemic and the need for effective treatments. Alector has benefited from the same positive trend in financials despite being one of the few companies not targeting COVID-19 treatments.

Alector, Inc: A Newer Biotech Company With Big Potential

Alector develops innovative therapeutic approaches for treating neurodegeneration. It is a critical stage biotechnology company.

Alector, Inc: A stock with its eyes on the future

SOUTH SAN FRANCISCO, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the appointment of Sara Kenkare-Mitra, Ph.D., as President and Head of Research and Development. In this newly created role, Dr. Kenkare-Mitra will lead all aspects of the company's immuno-neurology and oncology R&D efforts, including oversight of the research, development, clinical, manufacturing, regulatory, and related functions. Dr. Kenkare-Mitra will report to Arnon Rosenthal, Ph.D., Chief Executive Officer of Alector.

Alector Announces Appointment of Sara Kenkare-Mitra, Ph.D., as President and Head of Research and Development

News for Alector Inc Stock (ALEC)